Author

G. L. Coles

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 4 Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

J. Sage· 3 shared A. P. Drainas· 2 shared A. A. Adler· 1 shared A. Gras· 1 shared A. He· 1 shared A. Holzem· 1 shared A. L. He· 1 shared A. Niedecken· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Sage

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Development of pre-clinical murine models for fibrolamellar hepatocellular carcinoma

A. He, G. L. Coles, G. H. Hartmann, J. Arand, V. Le, B. Mauch, L. Xu, T. Nguyen, F. K. Hazard, J. Sage

This study develops a novel transgenic mouse model of fibrolamellar hepatocellular carcinoma (FLC) and highlights challenges in establishing ex vivo cell models from FLC tumors.

bioRxiv · Dec 6, 2023 · PreprintCancer Biology

A multiplexed in vivo approach to identify driver genes in small cell lung cancer

M. C. Lee, H. Cai, C. W. Murray, C. Li, Y. T. Shue, L. Andrejka, A. L. He, A. Holzem, A. P. Drainas, J. H. Ko, G. L. Coles, C. Kong, S. Zhu, C. Zhu, J. Wang, , J. Sage

The paper develops a multiplexed in vivo approach to identify driver genes in SCLC using CRISPR/Cas9 and lentiviral barcoding, finding TSC1 as a robust tumor suppressor.

bioRxiv · Mar 28, 2022Cancer Biology

Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy

E. L. Stone, K. P. Carter, E. K. Wagner, M. A. Asensio, E. Benzie, Y. Y. Chiang, G. L. Coles, C. Edgar, B. K. Gautam, A. Gras, J. Leong, R. Leong, V. A. Manickam, R. A. Mizrahi, A. Niedecken, , D. S. Johnson

This study shows that anti-CTLA-4 antibodies with reduced checkpoint inhibition have better anti-tumor efficacy and lower toxicity by primarily depleting tumor-infiltrating Tregs via FcR signaling.

bioRxiv · Jul 12, 2021 · PreprintImmunology

Spatial epitope barcoding reveals subclonaltumor patch behaviors

X. Rovira-Clave, A. P. Drainas, S. Jiang, Y. Bai, M. Baron, B. Zhu, M. Markovic, G. L. Coles, M. C. Bassik, J. Sage, G. P. Nolan

The paper develops a method to track subclonal tumor patch behaviors using spatial epitope barcoding and imaging, revealing emergent properties in cancer cell states.

bioRxiv · Jun 29, 2021 · PreprintCancer Biology